Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Cyclophosphamide-based Conditioning for Allogeneic Hematopoietic Stem Cell Transplant Save

Date Added
November 5th, 2019
PRO Number
Pro00091874
Researcher
Michelle Hudspeth

List of Studies


Profiles_link
Keywords
Cancer, Transplant
Summary

This study is for subjects that are about to receive high dose cyclophosphamide before a blood or bone marrow transplant (BMT). The investigational drug in this study is Olanzapine. This research is being done to find out whether adding olanzapine to standard medications will be helpful in controlling chemotherapy induced nausea in children. The total length of participation in this study will depend on how many days you are scheduled to receive chemotherapy, but can be up to a maximum of 2 weeks. We will review your chart for 100 days after transplant. There will be no extra visits to MUSC due to participating in the research study.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR??+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC "CSIDE" Protocol (Conditioning SCID Infants Diagnosed Early)PBMTC NMD 1801 Save

Date Added
November 5th, 2019
PRO Number
Pro00091878
Researcher
Michelle Hudspeth

List of Studies


Profiles_link
Keywords
Cancer, Infant, Pediatrics
Summary

This study is for children age 0-2 who have been diagnosed with severe combined immunodeficiency (SCID). In this study, participants will be randomized (select by chance) into groups that will decide the dose of chemotherapy they will receive, receive chemotherapy prior to a blood stem cell transplant, and have blood drawn for research tests. The purpose of this research study is to find out if lower doses of a chemotherapy drug called busulfan before stem cell transplant can help patients with SCID, and to see if the device the CliniMACS® is effective in preparing donor stem cells before the transplant. Participants can expect to be in this study for up to 3 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible Save

Date Added
October 25th, 2019
PRO Number
Pro00088478
Researcher
Theodore Gourdin

List of Studies

Silhouette
Keywords
Cancer, Cancer/Sarcoma, Men's Health, Women's Health
Summary

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone, both before and after radical cystectomy versus standard of care in participants with muscle invasive bladder cancer (MIBC) who are cisplatin ineligible. The treatment will be given to participants, who have bladder cancer that has invaded into the bladder muscle, and who cannot receive a chemotherapy treatment called cisplatin. The standard treatment in this situation is to have surgery to remove the bladder (radical cystectomy). In this trial, one-third of patients will be assigned to have NKTR-214 and nivolumab before and after surgery, one-third will have nivolumab before and after surgery, and one-third will have surgery alone. NKTR-214 and nivolumab are treatments that boost the immune system to fight cancer. It is unknown if NKTR-214 and nivolumab or nivolumab alone will have an effect (good, bad, or no effect) on the participant or their cancer.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA) Save

Date Added
October 22nd, 2019
PRO Number
Pro00088996
Researcher
Brian Hess

List of Studies

Silhouette
Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

This study is for patients who have been diagnosed with relapsed (the disease has gotten worse after a period of improvement) or refractory (the disease does not respond to treatment) aggressive B-cell non-Hodgkin lymphoma .The investigational therapy in this study is tisagenlecleucel treatment. This treatment includes collecting T cells from patient's blood and changing them by gene transfer to make them recognize tumor cells. The purpose of this study is to see how well tisagenlecleucel therapy treats the disease and how safe the treatment is when compared to Standard or Care treatment. Participants can expect to be in this study for up to 60 months and in follow up for up to 15 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Dermoscopic Features in Infantile Hemangiomas Save

Date Added
October 11th, 2019
PRO Number
Pro00091926
Researcher
Lara Wine lee

List of Studies

Silhouette
Keywords
Cancer, Cancer/Skin, Healthy Volunteer Studies, Infant, Non-interventional, Pediatrics, Rare Diseases
Summary

The goal of the study is to characterize the features of Infantile Hemangiomas before and after treatment. Certain characteristics of the hemangioma can be seen more clearly with a closer and more resolute image of the lesion (abnormal vessels etc.). Developing a greater understanding of these characteristics? may help clinicians better predict the course of infantile hemangiomas in children.

Specific aim 1: to correlate images seen on dermoscopy with regression of the hemangioma.
Specific aim 2: to provide features that may help to predict a better response to treatment.

Institution
MUSC
Recruitment Contact
Lara Wine Lee
8437922890
Winelee@musc.edu

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) Save

Date Added
October 10th, 2019
PRO Number
Pro00092018
Researcher
Theodore Gourdin

List of Studies

Silhouette
Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

Adult males are being asked to volunteer because they have been diagnosed to have bladder cancer that has spread and subjects tumor has a specific type of biomarker called PD-L1 (biomarkers can help to tell us what is going on in subjects body).This is a research study to find out if experimental medications called pembrolizumab and lenvatinib, when administered together. Participants can expect to be on this study for 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Save

Date Added
October 7th, 2019
PRO Number
Pro00090649
Researcher
Paul O'brien

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

This is a research study to compare the effects and safety, of tislelizumab plus chemotherapy to placebo (an inactive substance) plus chemotherapy on you and your Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJ) to find out the most effective treatment. The study will take place over 3 years 4 months and will include about 17-18 office -visits to the study doctor.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9300
hcc-clincal-trials@musc.edu

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies Save

Date Added
October 4th, 2019
PRO Number
Pro00086345
Researcher
Theodore Gourdin

List of Studies

Silhouette
Keywords
Cancer
Summary

This clinical study includes two phases, a "treatment phase" (i.e. phase during which subjects receive avelumab) and a "long-term follow up phase" (i.e. phase during which subjects are followed after stopping avelumab), which is the phase you are in. The purpose of the "long-term follow up phase" is to see if treatment with avelumab is safe and well tolerated, and how well the treatment worked in subjects like you who have been treated with avelumab in the past. This "long-term follow-up" portion may continue until a maximum of 5 years after the last participant in the clinical study receives the last dose of avelumab.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy Save

Date Added
September 23rd, 2019
PRO Number
Pro00091128
Researcher
Paul O'brien

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

The purpose of this study is to find out if cabozantinib in combination with atezolizumab is effective in treating liver cancer compared to sorafenib alone in people who have not received prior treatment. Subjects are being asked to take part in this clinical research study because they have hepatocellular carcinoma (liver cancer) that has not been previously treated for advanced disease.It is estimated that subjects will take study drug(s) for this study for approximately 1 to 6 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clincial-trials@musc.edu

A "Window Trial" on Curcumin, the Active Compound in Turmeric, for Invasive Breast Cancer Primary Tumors Save

Date Added
September 17th, 2019
PRO Number
Pro00087179
Researcher
Nancy Demore

List of Studies

Silhouette
Keywords
Cancer, Cancer/Breast
Summary

This study will assess the safety and toxicity of oral Curcuma longa extract (Curcumin) in patients with breast cancer.
The overall goal of this study is to see if taking BCM-95 (curcumin) will change the make up of the tumors of patients who have breast cancer. BCM-95 is a supplement made from the curcumin plant, which helps to reduce inflammation in the body. BCM-95 is not approved by the United State Food and Drug Administration (FDA) for the treatment of your disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-cto-clinops@musc.edu

Change_preferences

-- OR --

Create_login